|
ACCORD
Angioplastie Coronaire, Corvasal and Diltiazem
 |
Author(s) |
Lablanche J-M, Grollier G, Lusson J-R, Bassand J-P, Drobinski G, Bertrand B, Battaglia S, Desveaux B
|
 |
Title(s) |
Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty: the ACCORD study
|
|
Reference(s) |
Circulation 1997;95:83-9
|
|
Disease |
Angina or myocardial ischaemia with a significant stenosis
|
|
Purpose |
To study the effect of linsidomine and molsidomine on restenosis after PTCA
|
|
Study design |
Randomised, open, stratified for centre and single- or multivessel disease
|
|
Follow-up |
6 months
|
|
Patients |
723 patients
|
|
Treatment regimen |
Treatment group: linsidomine, 1 mg/h iv, started 3-18 h before PTCA. The dose was reduced if BP decreased > 10%. The infusion continued 24 h after PTCA, and 2 h before infusion stop molsidomine, 4 mg orally, was given. Molsidomine, 4 mg tid, was continued until follow-up angiography
Control group: diltiazem, 60 mg tid, started 3 h before PTCA and continuing until follow-up angiography
|
|
Concomitant therapy |
Aspirin, 250 mg daily, and iv heparin during PTCA
|
|
Results |
Pretreatment with linsidomine and molsidomine was associated with a modest but statistically significant improvement in the immediate angiographic result compared to diltiazem pretreatment (minimal luminal diameter 1.94 vs 1.81 mm). This improvement was maintained at the 6-month follow-up. Restenosis, defined as ≥ 50% stenosis, occurred less often in the linsidomine/molsidomine group (38.0% vs 46.5%; p = 0.026)
|
|
|
|
